GenePath Dx is a next generation diagnostics company that provides state-of-the-art in vitro diagnostic techniques such as molecular diagnostics to the medical, healthcare and allied communities.

We are committed to providing accurate, reliable, rapid and affordable diagnostics that are relevant and actionable. Our portfolio includes DNA and RNA based tests for Infectious Diseases, Oncology, Endocrinology, Transplantation typing, Haematology, Pharmacogenetics, and Pre-natal and pre-implantation genetic diagnostics.

We use advanced, but proven, platform technologies such as quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA) and Sanger and Next Generation Sequencing (NGS). Our molecular tests are more rapid compared to conventional microbiology and more sensitive than immunology based tests. For an increasing number of conditions, they are the only way to carry out a diagnosis.

GenePath Dx is an innovation-centric company with a strong emphasis on continuous R&D. We are constantly evolving in pace with global developments in the field and have the ability to develop new tests where needed, e.g. to respond to an emerging pathogen or a rare genetic disorder. We pride ourselves on our ability to work with clinicians to come up with novel or custom solutions to diagnostic problems.